TP53 and ovarian cancer: The TP53 signaling pathway (mutation rate 73%), the DNA‐damage response signaling pathway (mutation rate 36%), and the RTK signaling pathway (mutation rate 37.3%) were also mutated in drug‐sensitive recurrent ovarian cancer.